Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
7.58
-0.18 (-2.32%)
Jun 30, 2025, 2:52 PM - Market open
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Cullinan Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $30, which forecasts a 295.78% increase in the stock price over the next year. The lowest target is $22 and the highest is $36.
Price Target: $30 (+295.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 2 | 3 |
| Buy | 2 | 2 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 7 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $22 | Strong Buy | Initiates | $22 | +190.24% | Jun 11, 2025 |
| UBS | UBS | Strong Buy Maintains $30 → $24 | Strong Buy | Maintains | $30 → $24 | +216.62% | May 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +335.36% | Apr 16, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $38 → $35 | Buy | Initiates | $38 → $35 | +361.74% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +335.36% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
32.64M
EPS This Year
-3.32
from -3.11
EPS Next Year
-3.07
from -3.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 84.0M | 144.1M | ||
| Avg | n/a | 32.6M | 44.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 341.6% | ||
| Avg | - | - | 36.4% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.02 | -2.38 | -1.89 | ||
| Avg | -3.32 | -3.07 | -2.89 | ||
| Low | -3.55 | -3.75 | -3.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.